Prospectus 2016
Financial updatesProspectus 2016 is available for download.
Pharming Launches Rights Issue to raise €12.1 million as part of RUCONEST® North American Rights Acquisition Financing
Financial updatesPharming Group N.V. announces the launch of a 1 for 7 Rights Issue of up to 58,943,624 shares to raise approximately €12.1 million to existing shareholders its financing plans to enable the completion of the acquisition of the North American commercialization rights to RUCONEST® from Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) (“Valeant”), as announced on 9 August 2016 (the “Transaction”).
Pharming Announces Financing Plans for Closing of RUCONEST® North American Rights Acquisition
Financial updatesPharming Group N.V. announces its financing plans to enable the completion of the acquisition of the North American commercialization rights to RUCONEST® from Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) (“Valeant”), as announced on 9 August 2016.